ClinicalTrials.gg
RecruitingNCT03594344AHOLEAUpdated Mar 30, 2025

Additional Hyperbaric Oxygen After Lower Extremity Amputation

An interventional study of Hyperbaric oxygen therapy in Diabetes Mellitus, Claudication, Intermittent and Critical Limb Ischemia, sponsored by Oslo University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Primary conditionDiabetic FootRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's listed conditions name Diabetic Foot, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2018; still recruiting 8 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study evaluates the effect of additional hyperbaric oxygen therapy after lower extremity amputation. The patients will be randomized after amputation to either a treatment group receiving hyperbaric oxygen therapy, or control group.

Read the detailed description

Hyperbaric oxygen therapy has been used to treat hard to heal wounds for decades. Amputation, especially distal lower extremity amputations have the same problem with healing and patients often need to be re-amputated more proximally. In these patients oxygen levels are often the decisive factor. Providing additional oxygen under hyperbaric conditions will increase tissue oxygen concentration sufficient for the amputation stump to heal. This will give the patients a more distal amputation with better condition for ambulation.

02

Conditions studied

  • Diabetes Mellitus
  • Claudication, Intermittent
  • Critical Limb Ischemia
  • Osteomyelitis
  • Amputation
  • Lower Extremity Ulcer
  • Diabetic Angiopathy
  • Diabetic Neuropathies
  • Diabetic Foot

Keywords

  • Diabetic foot
  • Diabetes
  • Lower extremity amputation
  • Hyperbaric oxygen therapy
  • HBOT
03

In context

Diabetic Foot Reclassified

1,077 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 847 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 834 studies on the registry; 149 are open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lower extremity amputation because of chronic wound, osteomyelitis, ischemia, necrosis.
  • Fit to receive hyperbaric oxygen therapy determined by an anesthesiologist/Hyperbaric Medicine Physician.
  • Able to cooperate and follow up appointments
  • Included within 7 days after final surgery

Exclusion criteria

Exclusion Criteria:

  • Not fulfilling inclusion criteria
  • Pregnancy
  • Dementia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Hyperbaric oxygen therapy

    30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.

    Procedure: Hyperbaric oxygen therapy

  • No intervention
    Control group

    Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.

Interventions

  • ProcedureHyperbaric oxygen therapy

    Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions

06

What researchers measure

Primary outcomes

  1. Intact skin with no abnormal openings at the site of primary amputation

    Healed and intact skin at the site of primary amputation without need for more proximal amputation.Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon. Level of primary amputation is decided by the surgeon. Planned 2-session amputation, for example Guillotine amputation with a final amputation later is considered being primary amputation. Healed primary amputation will be measured at 12 weeks.

    Time frame: 12 weeks

Secondary outcomes

  1. Intact skin with no abnormal openings at the site of amputation at 6 months

    Healed and intact skin at the site of amputation at follow up 6 months. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

    Time frame: 6 months

  2. Intact skin with no abnormal openings at the site of amputation at 9 months

    Healed and intact skin at the site of amputation at follow up 9 months. Will be assessed if the wound has not healed at 6 months. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

    Time frame: 9 months

  3. Intact skin with no abnormal openings at the site of amputation at 1 year

    Healed and intact skin at the site of amputation at follow up at 1 year. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon.

    Time frame: 12 months

  4. Time to closed and intact skin at the site of amputation

    Time to closed and intact skin at the site of amputation is the defined as how many weeks until complete healing of amputation. Healed amputation is defined as epithelialization of the wound examined by a orthopedic surgeon and no abnormal openings.

    Time frame: 1 year

  5. Reamputations

    The total number of reamputations done within the follow-up period of 1 year.

    Time frame: 1 year

  6. Number of wound revision

    The total numbers of surgical wound revision done in operating theater.

    Time frame: 1 year

  7. Days in hospital during follow up

    Total number of days in hospital during 1 year follow up

    Time frame: 1 year

  8. Visual analog pain scale (VAS)

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

    Time frame: baseline

  9. Visual analog pain scale (VAS)

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

    Time frame: 12 weeks

  10. Visual analog pain scale (VAS)

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

    Time frame: 6 months

  11. Visual analog pain scale (VAS)

    Visual analog pain scale (VAS) is a measurement of pain intensity between 0 and 10. 0 = no pain, 10 = worst imaginable pain.

    Time frame: 1 year

  12. RAND 36-Item Short Form Health Survey

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

    Time frame: baseline

  13. RAND 36-Item Short Form Health Survey

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

    Time frame: 12 weeks

  14. RAND 36-Item Short Form Health Survey

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

    Time frame: 6 months

  15. RAND 36-Item Short Form Health Survey

    RAND 36-Item Short Form Health Survey (SF-36) measures 8 health domains with the total of 36 questions. The domains are physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. There is also 1 question that measures change in self-perceived health.The question answers is translated to a number between 0 meaning worst selv-perceived health and 100 meaning the best possible quality of health.Each domain will be presented with a number between 0 and 100.

    Time frame: 1 year

  16. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

    Time frame: baseline

  17. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

    Time frame: 12 weeks

  18. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

    Time frame: 6 months

  19. Quality of Life in Neurological Disorders - Lower extremity function - Mobility Short form

    Quality of Life in Neurological Disorders (Neuro-QoL) - Lower extremity function - Mobility Short form measures lower extremity function with 8 items scoring from 1 unable to do, to 5 which is doing it without any difficulty. Scores will be presented as total points from 5-40.

    Time frame: 1 year

  20. The Foot and Ankle Ability Measure (FAAM)

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

    Time frame: baseline

  21. The Foot and Ankle Ability Measure (FAAM)

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

    Time frame: 12 weeks

  22. The Foot and Ankle Ability Measure (FAAM)

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

    Time frame: 6 months

  23. The Foot and Ankle Ability Measure (FAAM)

    The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. FAAM contains 21 items that measure different functions. Each answer get a score from 0 to 4. The score total will be reported were 0 is the lowest and 84 is the highest possible score.

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Diakonhjemmet Hospital
    Oslo, 0319, Norway
    Recruiting
  • Orthopedic Center, Ullevål University Hopspital
    Oslo, 0407, Norway
    Recruiting
    • Elisabeth Ellingsen Husebye, MD, PhD · Contact+47 23027884
    • Jonas Rydinge · Contactjonryd@ous-hf.no · +47 92291795
    • Jonas Rydinge, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2025, 89 months after the start.

Of 240 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 89 months is above that.

Counting every sponsor, half of 343 studies reached it within 22 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Jul 20, 2018
StartActual
Jul 4, 2018
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03594344
Collaborators
Diakonhjemmet Hospital
Responsible party
Elisabeth Ellingsen Husebye (Principal Investigator, Oslo University Hospital) — Principal investigator
First posted
Jul 20, 2018
Start date
Jul 4, 2018
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 30, 2025

Study contacts

Jonas Rydinge, MD
Contact
jonryd@ous-hf.no
+4792291795 ext. +47 92291795
Elisabeth I Ellingsen Husebye, MD, PhD
Contact
uxngng@ous-hf.no
+47 95133773 ext. +47 95133773
Jonas V Rydinge, MD
principal investigator · Ullevål University Hospital, orthopedic department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion